Do these two new drugs (lecanemab and donanemab) work the same way aducanemab does? Does that mean that the aducanemab results weren't a fluke and that the amyloid plaque hypothesis may in fact be true?
Yes, Aducanumab may very well have had mild efficacy in the high dose group. But clearly the two newer drugs appear superior. Especially, when considering the side-effect profile.
It will be exciting to see how efficacious these amyloid-beta antibodies can become and there is also clearly a small mystery (or at least a lack of consensus) in why the newer drugs show efficacy and the previous ones all failed.
Maybe it's like "low serotonin levels" is to depression. A mechanism through which some effects are expressed, but not the root cause, and only one aspect of the condition.
